Fitzpatrick Wins Biotechnology-related Patent Interference No. 105,613 (RT)
Fitzpatrick attorneys won a judgment on behalf of client Amgen Inc. against Human Genome Sciences, Inc. and Schering Corp. in an interference involving rights to thymic stromal lymphopoietin receptor (TSLPR), a key receptor in the immune system. The USPTO granted Junior Party Amgen’s motion for judgment against all claims of Senior Parties HGS’s involved patent for lack of utility, particularly finding that HGS’s disclosure did not satisfy the requirement for a specific and substantial utility, and entered judgment against HGS in the interference.
Fitzpatrick Cella attorneys representing Amgen include Anthony M. Zupcic, Robert H. Fischer, Joseph P. Pieroni, and Stephen E. Belisle.